Lion Biotechnologies Inc. Daily Stock Analysis

Daily Stock Analysis, LBIO, Lion Biotechnologies Inc, priceseries

Lion Biotechnologies Inc. Daily Stock Analysis
Stock Information
Open
7.20
Close
6.95
High
7.20
Low
6.80
Previous Close
7.15
Daily Price Gain
-0.20
YTD High
8.30
YTD High Date
Mar 2, 2017
YTD Low
4.90
YTD Low Date
May 31, 2017
YTD Price Change
-0.30
YTD Gain
-4.14%
52 Week High
9.58
52 Week High Date
Aug 15, 2016
52 Week Low
4.90
52 Week Low Date
May 31, 2017
52 Week Price Change
-1.25
52 Week Gain
-15.24%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Dec 17. 2014
7.15
Jan 6. 2015
7.63
12 Trading Days
6.66%
Link
LONG
Jan 8. 2015
8.14
Jan 27. 2015
8.58
12 Trading Days
5.36%
Link
LONG
Mar 9. 2015
9.14
Mar 23. 2015
12.20
10 Trading Days
33.46%
Link
LONG
Mar 31. 2016
5.08
Apr 19. 2016
5.41
13 Trading Days
6.54%
Link
LONG
May 20. 2016
5.46
Jun 13. 2016
7.39
15 Trading Days
35.34%
Link
LONG
Jun 29. 2016
7.90
Jul 13. 2016
8.38
9 Trading Days
6.08%
Link
LONG
Nov 7. 2016
6.15
Nov 22. 2016
7.07
11 Trading Days
14.99%
Link
Company Information
Stock Symbol
LBIO
Exchange
NasdaqGM
Company URL
http://http://www.lbio.com
Company Phone
212-946-4826
CEO
Maria Fardis
Headquarters
New York
Business Address
112 WEST 34TH STREET, 17TH FLOOR, NEW YORK, NY 10120
Sector
-
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001425205
About

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells.

Description

Lion Biotechnologies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is LN-144, an adoptive cell therapy using tumor-infiltrating lymphocytes (TIL) that is in Phase II clinical trial, which are T cells derived from patients' tumors for the treatment of patients with refractory metastatic melanoma. It is also developing LN-145 to treat cervical and head and neck cancers. The company has a patent license agreement with the National Institutes of Health to develop, manufacture, and commercialize TIL therapies for the treatment of cervical, head and neck, bladder, lung, ovarian cancer, breast cancer, and colorectal cancers, as well as melanoma; cooperative research and development agreement with the National Institutes of Health and the National Cancer Institute to develop adoptive cell immunotherapies that are designed to destroy metastatic melanoma cells using a patient's tumor infiltrating lymphocytes; and manufacturing services agreement with Lonza Walkersville, Inc. and WuXi Apptech to manufacture, package, ship, and handle quality assurance and quality control of clinical trials for TIL products. The company was formerly known as Genesis Biopharma Inc. and changed its name to Lion Biotechnologies, Inc. in September 2013. Lion Biotechnologies, Inc. was founded in 2007 and is based in New York, New York.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading